K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecanor oxaliplatin-based chemotherapy

Cancer Biology and Therapy

Volumn 13, Issue 13, 2012, Pages 1235-1243

  Stec, Rafał ^a   Bodnar, Lubomir ^a   Charkiewicz, Radosław ^b   Korniluk, Jan ^a   Rokita, Marta ^a   Smoter, Marta ^a   Ciechowicz, Marzena ^a   Chyczewski, Lech ^b   Nikliński, Jacek ^b   Kozłowski, Wojciech ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Anti EGFR therapy; B Raf mutation; Colorectal cancer; Irinotecan; K Ras mutation; Oxaliplatin; RAS RAF mitogenactivated protein kinase

Indexed keywords

B RAF KINASE; CARCINOEMBRYONIC ANTIGEN; GENOMIC DNA; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CODON; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; EXON; FEMALE; GENDER; GENE MUTATION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84868340002     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21813     Document Type: Article

References (38)

1. The GLOBOCAN Project. http://globocan.iarc.fr/
2. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366:643-54; PMID:8259209; http://dx.doi.org/10.1038/366643a0.
3. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003; 17:1263-93; PMID:12835716; http://dx.doi.org/10. 1038/sj.leu.2402945.
4. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 2009; 8:1168-75; PMID:19282669; http://dx.doi.org/10.4161/cc.8.8.8147.
5. Czajkowski R, Placek W, Tadrowski T, et al. Geny BRAF, NRAS, HRAS w liniach komórkowych czerniaka ludzkiego. Przegl Dermatol 2009; 96:265-70.
6. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33:392-406; PMID:16890795; http://dx.doi.org/10.1053/j. seminoncol.2006.04.002.
7. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22; PMID:12509763; http://dx.doi.org/10.1038/nrc969.
8. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-9; PMID:2547513.
9. Nishimura S, Sekiya T. Human cancer and cellular oncogenes. Biochem J 1987; 243:313-27; PMID:3307760.
10. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006; 5:928-32; PMID:16969076; http://dx.doi.org/10.4161/cbt.5.8.3251.
11. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984; 312:71-5; PMID:6092966; http://dx.doi.org/10.1038/312071a0.
12. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007; 34:546-54; PMID:18083378; http://dx.doi.org/10. 1053/j.seminoncol.2007.09.011.
13. Nandan MO, Yang VW. An update on the biology of RAS/RAF mutations in colorectal cancer. Curr Colorectal Cancer Rep 2011; 7:113-20; PMID:21625338; http://dx.doi.org/10.1007/s11888-011-0086-1.
14. Shan W, Liu J. Epithelial ovarian cancer: focus on genetics and animal models. Cell Cycle 2009; 8:731- 5; PMID:19221485; http://dx.doi.org/10.4161/cc. 8.5.7848.
15. Khanafshar E, Lloyd RV. The spectrum of papillary thyroid carcinoma variants. Adv Anat Pathol 2011; 18:90-7; PMID:21169742; http://dx.doi.org/10. 1097/PAP.0b013e3182026da6.
16. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu- Duvaz D, Good VM, et al.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-67; PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54; PMID:12068308; http://dx.doi.org/10.1038/nature00766.
18. Cervera P, Fléjou JF. Changing pathology with changing drugs: tumors of the gastrointestinal tract. Pathobiology 2011; 78:76-89; PMID:21677471; http://dx.doi.org/10.1159/000315535.
19. Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009; 9:179; PMID:19515263; http://dx.doi.org/10.1186/1471-2407-9-179.
20. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16:790-9; PMID:20103678; http://dx.doi.org/10.1158/1078-0432.CCR-09-2446.
21. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-62;PMID:20619739; http://dx.doi.org/10.1016/S1470-2045(10)70130-3.
22. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-30; PMID:19884556; http://dx.doi.org/10.1200/JCO.2008.21.6796.
23. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931-7; PMID:19884549; http://dx.doi.org/10.1200/JCO.2009.22.4295.
24. Van Cutsem E, Rougier P, Köhne CH. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status. ECCO-ESMO 2009; Abstr.No: 6.077.
25. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-8; PMID:18003960; http://dx.doi.org/10.1056/NEJMoa071834.
26. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10. 1056/NEJMoa0804385.
27. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697-705; PMID:20921465; http://dx.doi.org/10.1200/JCO.2009.27.4860.
28. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011; 26:823-33; PMID:21286919; http://dx.doi.org/10.1007/s00384- 011-1149-0.
29. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010; 46:1997-2009; PMID:20413299; http://dx.doi.org/10.1016/j.ejca.2010. 03.036.
30. Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010; 21:2396-402; PMID:20501503; http://dx.doi.org/10.1093/annonc/ mdq258.
31. Lagautrière F, Valvano L, Chaazl M, Benchimol D, Bernard JL, Bourgeon A, et al. [Prognostic factors in colorectal adenocarcinoma]. Ann Ital Chir 1998; 69:491-6, discussion 496-7; PMID:9835125.
32. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al.; Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343:905-14; PMID:11006366; http://dx.doi.org/10.1056/NEJM200009283431302.
33. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26:1443-51; PMID:18349394; http://dx.doi.org/10.1200/JCO.2007.14.0509.
34. Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum 2009; 52:1359-66; PMID:19617745; http://dx.doi.org/10.1007/DCR.0b013e3181a7b7de.
35. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-18, discussion 318-21; PMID:10493478; http://dx.doi.org/10.1097/00000658-199909000-00004.
36. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705-12; PMID:19001320; http://dx.doi.org/10.1200/JCO.2008.18.0786.
37. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:4706-13; PMID:20921462; http://dx.doi.org/10.1200/JCO.2009.27.6055.
38. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009; 6:528-34; PMID:19597509; http://dx.doi. org/10.1038/nrclinonc.2009.106.